期刊
CANCER CELL
卷 33, 期 4, 页码 563-569出版社
CELL PRESS
DOI: 10.1016/j.ccell.2018.03.008
关键词
-
资金
- NIH [R01 CA169123, P01 CA210944, P30 CA016520]
- Parker Institute for Cancer Immunotherapy
- Stand Up 2 Cancer-Lustgarten Foundation
- Breast Cancer Research Foundation
- Penn's Basser Center for BRCA
- Abramson Cancer Center
Most tumors are unresponsive to immune checkpoint blockade, especially if deep immunosuppression in the tumor develops prior to and prevents T cell immunosurveillance. Failed or frustrated T cell priming often needs repair before successful sensitization to PD-1/PD-L1 blockade. CD40 activation plays a critical role in generating T cell immunity, by activating dendritic cells, and converting cold tumors to hot. In preclinical studies, agonistic CD40 antibodies demonstrate T cell-dependent anti-tumor activity, especially in combination with chemotherapy, checkpoint inhibitory antibodies, and other immune modulators. With the advent of multiple CD40 agonists with acceptable single-agent toxicity, clinical evaluation of CD40 combinations has accelerated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据